SLGL Overview

Clinical Study Update: Sol-Gel Technologies announced that the Phase 1b study of SGT-210 for Darier disease did not show efficacy compared to the vehicle, leading to a decision not to advance further in this indication. The company plans to conduct small feasibility studies in other areas of unmet medical need.

Focus on Other Programs: The Executive Chairman, Mori Arkin, emphasized the company's commitment to completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparing for a potential Phase 3 program in high-frequency basal cell carcinoma, contingent on the success of the Gorlin trial.

Stock Performance Analysis: Sol-Gel Technologies (SLGL) is currently showing strong technical indicators, trading above key moving averages, with a bullish trend supported by positive momentum in the MACD and a neutral RSI.

Recent Stock Movement: SLGL stock experienced a decline of 6.81% to $39.26, while over the past year, it has gained 735.02%, indicating a strong upward trajectory but caution is advised as it approaches resistance levels.

Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including DraftKings, Avidity Biosciences, and Glaukos Corp, reflecting a mix of upgrades and downgrades.

Notable Price Target Increases: Avidity Biosciences saw its price target raised significantly by Bernstein, while Exagen and Estee Lauder also received upward adjustments from Canaccord Genuity.

Upgrades and Downgrades: Glaukos Corp was upgraded by Wells Fargo, while Kura Sushi USA experienced a downgrade from Benchmark, despite both maintaining Buy ratings.

Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.

Regulatory Approval: Sol-Gel Technologies Ltd. received Health Canada's approval for EPSOLAY, a topical cream for treating rosacea, marking a significant expansion beyond the U.S. market.

Stock Performance and Financial Outlook: Following the approval, SLGL shares surged nearly 20%, and the company anticipates up to $11 million in milestone payments and royalties from EPSOLAY and TWYNEO in Canada, with further international launches expected to enhance revenue by 2031.